AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31515632 — intervention group
Group type: COMPARATOR
Intervention: Both NZBC extract and PL
Number of subjects: 18
Study 29772028 — intervention group
Group type: EXPERIMENTAL
Intervention: CPHPC (miridesap) for SAP depletion prior to DNA vaccination
Number of subjects: 0
Study 29772028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SAP depletion)
Number of subjects: 0
Study 26831857 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation-assisted TKA
Number of subjects: 80
Study 26831857 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 80
Study 25030803 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Number of subjects: 120
Study 25030803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 22851599 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic intervention
Number of subjects: 0
Study 22851599 — intervention group
Group type: COMPARATOR
Intervention: Active control (print intervention)
Number of subjects: 0
Study 20800270 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermo-mechanical loading (TML; 100,000×50N; 2500×+5/+55°C)
Number of subjects: 30
Study 20800270 — intervention group
Group type: EXPERIMENTAL
Intervention: Water storage (WS)
Number of subjects: 30
Study 20800270 — intervention group
Group type: EXPERIMENTAL
Intervention: Water storage plus thermo-mechanical loading (WS+TML)
Number of subjects: 30
Study 20800270 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct resin composite restorations (in vivo)
Number of subjects: 30
Study 18583016 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive voice and video instruction (video group)
Number of subjects: 96
Study 18583016 — intervention group
Group type: COMPARATOR
Intervention: Voice instruction alone (voice group)
Number of subjects: 96
Study 16647134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaptanib sodium (0.3 mg)
Number of subjects: 1190
Study 16647134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaptanib sodium (1 mg)
Number of subjects: 1190
Study 16647134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaptanib sodium (3 mg)
Number of subjects: 1190
Study 16647134 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 1190
Study 12960445 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg hydroxy‐progesterone caproate and 10 mg oestradiol valerate on days 2, 6, 10 and 14 after embryo transfer (group 2, n = 411)
Number of subjects: 603
Study 12960445 — intervention group
Group type: COMPARATOR
Intervention: 5000 iu human chorionic gonadotrophin (hCG) 4 and 8 days after embryo transfer (group 1, n = 534)
Number of subjects: 603
Study 10731545 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop Color Word test and blood sampling in patients with FHSA
Number of subjects: 90
Study 10731545 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop Color Word test and blood sampling in patients with PCOS
Number of subjects: 90
Study 10731545 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 90
Study 10731545 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PCOS
Number of subjects: 90
Study 9491671 — intervention group
Group type: EXPERIMENTAL
Intervention: Late progesterone phase
Number of subjects: 53
Study 9491671 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular menstrual cycles
Number of subjects: 53
Study 1550514 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotope renography
Number of subjects: 63
Study 1550514 — intervention group
Group type: COMPARATOR
Intervention: Arteriography
Number of subjects: 63
Study 2866057 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 0
Study 2866057 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 2866057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31191092 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Rolling (FOAM, n = 14)
Number of subjects: 40
Study 31191092 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stabilization (CORE, n = 12)
Number of subjects: 40
Study 31191092 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG, n = 12)
Number of subjects: 40
Study 28813214 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 1204
Study 28813214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1204
Study 26216931 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 124
Study 26216931 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 124
Study 26216931 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (early)
Number of subjects: 124
Study 26216931 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (late)
Number of subjects: 124
Study 26216931 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor (early)
Number of subjects: 124
Study 26216931 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor (late)
Number of subjects: 124
Study 24305430 — intervention group
Group type: EXPERIMENTAL
Intervention: Test foaming liquid facial cleanser containing HMPs
Number of subjects: 40
Study 24305430 — intervention group
Group type: COMPARATOR
Intervention: Commercial gentle liquid nonfoaming facial cleanser
Number of subjects: 40
Study 21532082 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentor plus usual care
Number of subjects: 74
Study 21532082 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 74
Study 18054000 — intervention group
Group type: EXPERIMENTAL
Intervention: SIVF catheter
Number of subjects: 400
Study 18054000 — intervention group
Group type: COMPARATOR
Intervention: EW catheter
Number of subjects: 400
Study 16941701 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-interferon alpha-2b (PEG-IFN) and lamivudine
Number of subjects: 266
Study 16941701 — intervention group
Group type: COMPARATOR
Intervention: PEG-interferon alpha-2b (PEG-IFN) monotherapy
Number of subjects: 266
Study 12953339 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 128
Study 12953339 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 128
Study 12953339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 128
Study 10743815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral SI joint injections of triamcinolone hexacetonide (40 mg/joint) under computer tomographic guidance
Number of subjects: 19
Study 10743815 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as patients without treatment)
Number of subjects: 19
Study 8614505 — intervention group
Group type: EXPERIMENTAL
Intervention: d-cycloserine (15 mg)
Number of subjects: 108
Study 8614505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 1390591 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (40 mg/day) + n-3 polyunsaturated fatty acids (5.3 g eicosapentaenoic and docosahexaenoic acids)
Number of subjects: 6
Study 1390591 — intervention group
Group type: COMPARATOR
Intervention: n-6 polyunsaturated fatty acids (control)
Number of subjects: 6
Study 1390591 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (5.3 g)
Number of subjects: 6
Study 2861223 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexamethonium bromide plus placebo
Number of subjects: 6
Study 2861223 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexamethonium bromide alone
Number of subjects: 6
Study 2861223 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexamethonium bromide plus atropine sulphate
Number of subjects: 6
Study 2861223 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 6
Study 28861602 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 56
Study 28861602 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 56
Study 29469944 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum three times a day for 30 minutes
Number of subjects: 2000
Study 29469944 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care (Control)
Number of subjects: 2000
Study 29469944 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 2000
Study 29469944 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2000
Study 26851700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 62
Study 26851700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 25178312 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric screening and intervention
Number of subjects: 780
Study 25178312 — intervention group
Group type: COMPARATOR
Intervention: Standard ED care
Number of subjects: 780
Study 22316799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic intervention including biofeedback
Number of subjects: 66
Study 22316799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic intervention without biofeedback
Number of subjects: 66
Study 22316799 — intervention group
Group type: COMPARATOR
Intervention: Control group without intervention
Number of subjects: 66
Study 21130326 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-seal (light-cured filled resin)
Number of subjects: 100
Study 21130326 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Vanish)
Number of subjects: 100
Study 21130326 — intervention group
Group type: COMPARATOR
Intervention: Aegis-Ortho (ACP cement)
Number of subjects: 100
Study 21130326 — intervention group
Group type: COMPARATOR
Intervention: MI Paste (casein phosphopeptide-ACP paste)
Number of subjects: 100
Study 21130326 — intervention group
Group type: COMPARATOR
Intervention: Control (Transbond XT resin)
Number of subjects: 100
Study 17595895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin test formulation (Novell Pharmaceutical Laboratories, Indonesia)
Number of subjects: 24
Study 17595895 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin reference formulation (Quimica Farmaceutica Bayer, Spain)
Number of subjects: 24
Study 15771028 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasojejunal tube (NJT) placement
Number of subjects: 237
Study 15771028 — intervention group
Group type: COMPARATOR
Intervention: No nasojejunal tube (no-NJT) placement
Number of subjects: 237
Study 12495602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 1 to 2 g IV twice daily or three times a day for 3 to 21 days
Number of subjects: 317
Study 12495602 — intervention group
Group type: COMPARATOR
Intervention: Broad-spectrum combination therapy (IV ampicillin, cephalothin, or ceftriaxone +/- aminoglycoside) for 3 to 21 days
Number of subjects: 317
Study 12495602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 317
Study 12495602 — intervention group
Group type: COMPARATOR
Intervention: Broad-spectrum combination therapy
Number of subjects: 317
Study 9577999 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose gabapentin monotherapy (3,000‐4,800 mg/day)
Number of subjects: 45
Study 9327485 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly newsletter
Number of subjects: 345
Study 9327485 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help behavior change kit
Number of subjects: 345
Study 9327485 — intervention group
Group type: EXPERIMENTAL
Intervention: Both materials
Number of subjects: 345
Study 9327485 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic correlates
Number of subjects: 345
Study 2021990 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 40 mg iv pretreatment with cimetidine 200 mg iv
Number of subjects: 0
Study 2021990 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 200 mg iv without diphenhydramine pretreatment
Number of subjects: 0
Study 7214686 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide (30 mg/capsule, 2-4 capsules daily)
Number of subjects: 41
Study 7214686 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine (5 mg/capsule, 2-4 capsules daily)
Number of subjects: 41
Study 30741797 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix (40 mg, oral, once daily)
Number of subjects: 288
Study 30741797 — intervention group
Group type: COMPARATOR
Intervention: Leuprorelin (1.88 mg or 3.75 mg, monthly injection)
Number of subjects: 288
Study 30741797 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix
Number of subjects: 288
Study 30741797 — intervention group
Group type: COMPARATOR
Intervention: Leuprorelin
Number of subjects: 288
Study 30741797 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix and Leuprorelin
Number of subjects: 288
Study 27749616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided steroid injection (40 mg of methylprednisolone)
Number of subjects: 47
Study 27749616 — intervention group
Group type: COMPARATOR
Intervention: Landmark-guided steroid injection (40 mg of methylprednisolone)
Number of subjects: 47
Study 23653426 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg donepezil
Number of subjects: 15
Study 23653426 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5-mg donepezil
Number of subjects: 15
Study 23653426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 21854068 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein hydrolysate (PPH) administered orally at doses of 100 and 200 mg/kg body weight to SHR; 3-week randomized double-blind placebo-controlled trial in humans.
Number of subjects: 7
Study 21854068 — intervention group
Group type: COMPARATOR
Intervention: Unhydrolyzed pea protein isolate (PPI) administered orally to SHR.
Number of subjects: 7
Study 19955890 — intervention group
Group type: EXPERIMENTAL
Intervention: AWS (PENTAX-AWS)
Number of subjects: 40
Study 19955890 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 40
Study 17586102 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin 10‐20mg/day
Number of subjects: 8214
Study 17586102 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 8214
Study 15792017 — intervention group
Group type: EXPERIMENTAL
Intervention: VIBOVITmama supplementation (15 mg of zinc, 2 mg of copper, 20 microg of selenium)
Number of subjects: 138
Study 15792017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 15792017 — intervention group
Group type: EXPERIMENTAL
Intervention: VIBOVITmama supplementation
Number of subjects: 138
Study 11728483 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol orally
Number of subjects: 499
Study 11728483 — intervention group
Group type: COMPARATOR
Intervention: 10 IU oxytocin intramuscularly
Number of subjects: 499
Study 9008373 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selection based on gender-linked differences in support for group inequality (social dominance orientation)
Number of subjects: 0
Study 9008373 — intervention group
Group type: EXPERIMENTAL
Intervention: Hiring biases based on matching job applicants' group equality values with the hierarchy function of the job
Number of subjects: 0
Study 9008373 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-stereotyped hiring biases
Number of subjects: 0
Study 8331198 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 0
Study 8331198 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg
Number of subjects: 0
Study 3013265 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20-40 mg plus hydrochlorothiazide 25-100 mg
Number of subjects: 0
Study 3013265 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50-100 mg plus hydrochlorothiazide 25-100 mg
Number of subjects: 0
Study 3013265 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 3013265 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study 3013265 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril plus hydrochlorothiazide
Number of subjects: 0
Study 3013265 — intervention group
Group type: COMPARATOR
Intervention: Atenolol plus hydrochlorothiazide
Number of subjects: 0
Study 29254067 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry induction
Number of subjects: 171
Study 29254067 — intervention group
Group type: COMPARATOR
Intervention: Relaxation induction
Number of subjects: 171
Study 29254067 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry induction in GAD
Number of subjects: 171
Study 29254067 — intervention group
Group type: COMPARATOR
Intervention: Relaxation induction in GAD
Number of subjects: 171
Study 29254067 — intervention group
Group type: COMPARATOR
Intervention: Worry induction in Controls
Number of subjects: 171
Study 29254067 — intervention group
Group type: COMPARATOR
Intervention: Relaxation induction in Controls
Number of subjects: 171
Study 27199056 — intervention group
Group type: EXPERIMENTAL
Intervention: Papillary muscle approximation with undersizing restrictive mitral annuloplasty (PMA)
Number of subjects: 96
Study 27199056 — intervention group
Group type: COMPARATOR
Intervention: Restrictive annuloplasty (RA)
Number of subjects: 96
Study 24128996 — intervention group
Group type: EXPERIMENTAL
Intervention: LiquiBand Surgical S (LB)
Number of subjects: 433
Study 24128996 — intervention group
Group type: COMPARATOR
Intervention: High Viscosity Dermabond (DB)
Number of subjects: 433
Study 22336104 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT)
Number of subjects: 51
Study 22336104 — intervention group
Group type: COMPARATOR
Intervention: Action Research Arm Test (ARAT)
Number of subjects: 51
Study 22336104 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor and kinematic measures of reach and grasp
Number of subjects: 51
Study 22336104 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical measures of disability
Number of subjects: 51
Study 20231319 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-cognitive therapy
Number of subjects: 88
Study 20231319 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 88
Study 18435955 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Stents (PES)
Number of subjects: 956
Study 18435955 — intervention group
Group type: COMPARATOR
Intervention: Bare Metal Stents (BMS)
Number of subjects: 956
Study 15863811 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 97
Study 15863811 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 97
Study 15863811 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotic medication
Number of subjects: 97
Study 12431860 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 14
Study 12431860 — intervention group
Group type: COMPARATOR
Intervention: Control mixture
Number of subjects: 14
Study 10348762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin applied to the anterior nares for 5 days
Number of subjects: 102
Study 10348762 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied to the anterior nares for 5 days
Number of subjects: 102
Study 7782178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate ear drops
Number of subjects: 110
Study 7782178 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide ear drops
Number of subjects: 110
Study 7782178 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 110
Study 1887981 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation
Number of subjects: 60
Study 1887981 — intervention group
Group type: COMPARATOR
Intervention: Orotracheal intubation
Number of subjects: 60
Study 6355186 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (15 mg/d per subject for 7 days)
Number of subjects: 10
Study 31376437 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme spicy food cravers
Number of subjects: 51
Study 31376437 — intervention group
Group type: COMPARATOR
Intervention: Non-cravers
Number of subjects: 51
Study 28248154 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (low-intensity intervention including behavioral activation delivered by a case manager for an average of six sessions over 7-8 weeks, alongside usual GP care)
Number of subjects: 705
Study 28248154 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 705
Study 28248154 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 705
Study 26619086 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 1465
Study 24313916 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 100 mg plus MTX
Number of subjects: 316
Study 24313916 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg plus MTX
Number of subjects: 316
Study 24313916 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg plus MTX
Number of subjects: 316
Study 24313916 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 316
Study 22523181 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of supervised aerobic exercise training (AET)
Number of subjects: 122
Study 22523181 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 122
Study 19670459 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 67
Study 19670459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 17584318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin administered before meals (group B)
Number of subjects: 37
Study 17584318 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin administered after meals (group A)
Number of subjects: 37
Study 15155118 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 0
Study 15155118 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 0
Study 15155118 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan plus Ramipril
Number of subjects: 0
Study 15155118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11238232 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of ETEC vaccine
Number of subjects: 0
Study 11238232 — intervention group
Group type: EXPERIMENTAL
Intervention: First dose of ETEC vaccine
Number of subjects: 0